Literature DB >> 3475037

Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)].

M Ito, H Nakashima, M Baba, R Pauwels, E De Clercq, S Shigeta, N Yamamoto.   

Abstract

Glycyrrhizin (GL), one of the plant extracts, was investigated for its antiviral action on the human immunodeficiency virus [HIV (HTLV-III/LAV)] in vitro, using cytopathic effect and plaque forming assay system in MT-4 cells (a HTLV-I-carrying cell line). Cloned Molt-4 cells (clone No. 8), which are sensitive to HIV and fuse to giant cells after infection, were also used as a parameter for cytopathic effect of HIV. GL completely inhibited HIV-induced plaque formation in MT-4 cells at a concentration of 0.6 mM, the 50% inhibitory dose being 0.15 mM. GL completely inhibited the cytopathic effect of HIV and the HIV-specific antigen expression in MT-4 cells at a concentration of 0.3 and 0.6 mM, respectively. Furthermore, GL inhibited giant cell formation of HIV-infected Molt-4 clone No. 8 cells. GL had no direct effect on the reverse transcriptase of HIV. Its mechanism of anti-HIV action remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3475037     DOI: 10.1016/0166-3542(87)90001-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  37 in total

Review 1.  Plant products as antimicrobial agents.

Authors:  M M Cowan
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

2.  Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol.

Authors:  T S Lin; R Schinazi; B P Griffith; E M August; B F Eriksson; D K Zheng; L A Huang; W H Prusoff
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

3.  Gene regulation patterns in triterpene biosynthetic pathway driven by overexpression of squalene synthase and methyl jasmonate elicitation in Bupleurum falcatum.

Authors:  Young Soon Kim; Jung Hyun Cho; Sangkyu Park; Jung-Yeon Han; Kyoungwhan Back; Yong-Eui Choi
Journal:  Planta       Date:  2010-10-30       Impact factor: 4.116

4.  Effectiveness of glycyrrhizin for oral lichen planus in patients with chronic HCV infection.

Authors:  Y Da Nagao; M Sata; H Suzuki; K Tanikawa; K Itoh; T Kameyama
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

5.  Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine.

Authors:  M S Smith; E L Brian; E De Clercq; J S Pagano
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  Triterpene functional genomics in licorice for identification of CYP72A154 involved in the biosynthesis of glycyrrhizin.

Authors:  Hikaru Seki; Satoru Sawai; Kiyoshi Ohyama; Masaharu Mizutani; Toshiyuki Ohnishi; Hiroshi Sudo; Ery Odette Fukushima; Tomoyoshi Akashi; Toshio Aoki; Kazuki Saito; Toshiya Muranaka
Journal:  Plant Cell       Date:  2011-11-29       Impact factor: 11.277

Review 7.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

8.  EST analysis reveals putative genes involved in glycyrrhizin biosynthesis.

Authors:  Ying Li; Hong-Mei Luo; Chao Sun; Jing-Yuan Song; Yong-Zhen Sun; Qiong Wu; Ning Wang; Hui Yao; André Steinmetz; Shi-Lin Chen
Journal:  BMC Genomics       Date:  2010-04-28       Impact factor: 3.969

Review 9.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

10.  Modulation by glycyrrhetinic acid derivatives of TPA-induced mouse ear oedema.

Authors:  H Inoue; T Mori; S Shibata; Y Koshihara
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.